The Role of Biomarkers in Cardio- Oncology
Medical Health News,
1. Dolci, A.,
1. Dolci, A.,
VANCOUVER, British Columbia, Feb. 27, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc.
No evidence of cardiotoxicity to date; 40% of 10 patients dosed at ≥120 mg/m² demonstrate efficacy; trial progresses in Europe…
VANCOUVER, British Columbia, Feb. 27, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc.
VANCOUVER, British Columbia, Feb. 27, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc.
VANCOUVER, British Columbia, Feb. 27, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc.
VANCOUVER, British Columbia, Feb. 27, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc.
VANCOUVER, British Columbia, Feb. 27, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc.
No evidence of cardiotoxicity to date; 40% of 10 patients dosed at ≥120 mg/m² demonstrate efficacy; trial progresses in Europe…
No evidence of cardiotoxicity to date; 40% of 10 patients dosed at ≥120 mg/m² demonstrate efficacy; trial progresses in Europe…
No evidence of cardiotoxicity to date; 40% of 10 patients dosed at ≥120 mg/m² demonstrate efficacy; trial progresses in Europe…
No evidence of cardiotoxicity to date; 40% of 10 patients dosed at ≥120 mg/m² demonstrate efficacy; trial progresses in Europe…
HOUSTON, Feb. 5, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage…
PALM BEACH, Florida, Feb. 5, 2020 /PRNewswire/ -- Acute Myeloid Leukemia (AML) research has seen great progress with more…
HOUSTON, Feb. 5, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage…
HOUSTON, Feb. 5, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage…
HOUSTON, Feb. 5, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage…
Moleculin to Seek Accelerated FDA Approval and Plans for Pivotal Phase 2 AML Trial Following Successful Completion of US Phase…
HOUSTON, Feb. 5, 2020 / / -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a clinical stage…
Following Successful Completion of US Phase 1 Trial HOUSTON, Feb. 5, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX…
Following Successful Completion of US Phase 1 Trial HOUSTON, Feb. 5, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX…
HOUSTON, Feb. 3, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage…
HOUSTON, Feb. 3, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage…
HOUSTON, Feb. 3, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage…
, /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical…
No evidence of cardiotoxicity; preliminary assessment shows efficacy in 2 out of 6 patients; Company updates interim Phase 1…
SOURCE Moleculin Biotech, Inc. No evidence of cardiotoxicity; preliminary assessment shows efficacy in 2 out of 6 patients…
SOURCE Moleculin Biotech, Inc. No evidence of cardiotoxicity; preliminary assessment shows efficacy in 2 out of 6 patients…
HOUSTON, Feb. 3, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage…
HOUSTON, Feb. 3, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage…
PR Newswire HOUSTON, Feb. 3, 2020 HOUSTON, Feb. 3, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or…
. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of oncology drug candidates for…
Moleculin Announces Successful Completion of US Phase 1 AML Trial of Annamycin No evidence of cardiotoxicity; preliminary…
HOUSTON, Feb. 3, 2020 /PRNewswire/ --., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company…
HOUSTON, Feb. 3, 2020 / / -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a clinical stage…
HOUSTON, Feb. 3, 2020 /PRNewswire/ --., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company…
No evidence of cardiotoxicity; preliminary assessment shows efficacy in 2 out of 6 patients; Company updates interim Phase 1…
An additional patient in the US has begun treatment at 120 mg/m2 but has yet to complete post-treatment evaluation.
SOURCE Moleculin Biotech, Inc. No evidence of cardiotoxicity to date; 40% of 10 patients dosed at =120 mg/m² demonstrate…
SOURCE Moleculin Biotech, Inc. No evidence of cardiotoxicity to date; 40% of 10 patients dosed at =120 mg/m² demonstrate…
HOUSTON, Dec. 4, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage…
Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad…
SOURCE Moleculin Biotech, Inc. No evidence of cardiotoxicity to date; 40% of 10 patients dosed at =120 mg/m² demonstrate…
SOURCE Moleculin Biotech, Inc. No evidence of cardiotoxicity to date; 40% of 10 patients dosed at =120 mg/m² demonstrate…
Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad…
SOURCE Moleculin Biotech, Inc. No evidence of cardiotoxicity to date; 40% of 10 patients dosed at =120 mg/m² demonstrate…
Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad…
PR Newswire HOUSTON, Dec. 4, 2019 HOUSTON, Dec. 4, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or…
Moleculin Announces Additional Positive Interim Results from Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia…
HOUSTON, Dec. 4, 2019 / / -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a clinical stage…
No evidence of cardiotoxicity to date; 40% of 10 patients dosed at ≥120 mg/m² demonstrate efficacy; trial progresses in Europe…
. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of oncology drug candidates for…
HOUSTON, Dec. 4, 2019 /PRNewswire/ -- Moleculin Biotech Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage…